


 Cite this: *RSC Adv.*, 2026, 16, 22261

Metal-free Minisci C–H alkylation of hydrazones using aldehydes: an unexpected route to hydrazone-containing pyrimidine derivatives

 Atefeh Tirehdast,^a Volodymyr Semeniuchenko ^b and Ali Shiri ^{*a}

In this research, a novel method for synthesizing various heterocyclic derivatives *via* the Minisci radical substitution reaction has been presented. The Minisci reaction offers a very efficient and valuable approach for directly functionalizing heteroarenes with an electron-deficient group, allowing the formation of carbon–carbon bonds straightforwardly and efficiently. We have developed a metal-free, light-independent Minisci-type strategy for the direct C–H functionalization of pyrimidines, thereby facilitating the design of heteroaromatic derivatives containing hydrazone groups. The target derivatives were successfully synthesized in good yields using aromatic aldehydes as alkyl radical precursors. The reaction proceeds through a sequence of hydrogen atom abstraction (HAA) from the aldehyde, followed by decarbonylation under oxidative conditions using $K_2S_2O_8$ and trifluoroacetic acid (TFA). This method provides a practical and scalable approach to accessing structurally heterocyclic compounds of various classes.

Received 19th February 2026

Accepted 23rd April 2026

DOI: 10.1039/d6ra01465h

rsc.li/rsc-advances

Introduction

The Minisci reaction, first developed in the late 1960s by Francesco Minisci, is a significant strategy for the direct radical functionalization of electron-deficient nitrogen-containing heteroarenes.^{1–5} One of the key advantages of this process is its ability to directly attach alkyl and aryl groups onto heteroaromatic frameworks without needing prior substrate activation.^{6–11} This notable property has made the Minisci reaction essential for the synthesis of complex bioactive compounds and producing pharmaceuticals and important synthetic intermediates.^{12–14}

Even if there are such merits, classical Minisci protocols generally experience inherent deficiencies. The traditional protocols generally rely on metal catalysis, photochemical initiation, or stoichiometric amounts of strong oxidants.¹⁵ Such needs not only become prohibitively expensive and environmentally unfavorable but also impose severe limitations on scalability and functional group toleration.^{16–19} Consequently, efforts in the recent past were aimed at the synthesis of more practical alternatives. Metal-free and photocatalyst-free forms became the future Minisci-type protocols through the accomplishment of the conversion under milder, more sustainable conditions, in alignment with the principles of the green chemistry movement.^{20–24} Of the many radical precursors

studied for Minisci reactions, the aldehyde case is particularly unique.²⁵ It simplifies the process by inclusion of aldehydes, and offers access to a vast new product range.^{26–28}

Recent studies have demonstrated that aldehydes can serve as effective radical precursors in Minisci-type C–H functionalization of heteroarenes. In several reported systems, these transformations proceed under visible-light irradiation through photochemically initiated radical pathways.²⁹ In addition, related approaches have utilized metal catalysts in combination with oxidants to enable oxidative C–H functionalization using aldehydes as coupling partners.³⁰ While these studies highlight the versatility of aldehydes in radical C–H functionalization chemistry, many of the existing methods rely on either external light sources or metal catalysts. In contrast, the present study describes a metal-free and light-independent Minisci-type protocol for the C–H functionalization of pyrimidines using readily available aldehydes, providing straightforward access to hydrazone-containing heterocyclic derivatives.

On the other hand, pyrimidines, among the nitrogen heterocycles, have long been a focus of medicinal chemists due to their vast array of biological activities, including anticancer,³¹ antiviral,^{32,33} antibacterial,^{34,35} and enzyme inhibitory properties.^{36,37} Their unique properties and strong ability to engage biological targets render them popular scaffolds in modern drug design. Moreover, hydrazone-containing frameworks have attracted significant attention owing to their diverse biological properties, including anticancer, anti-inflammatory, antifungal, and antiviral activities.^{38,39} The incorporation of the hydrazone substructures on heteroaromatic rings such as pyrimidines has the potential to endow heterocycles with promising

^aDepartment of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran. E-mail: alishiri@um.ac.ir

^bDepartment of Chemistry and Biomolecular Sciences, Faculty of Science, University of Ottawa, Ottawa, Canada






Fig. 1 Representative natural products and drugs with hydrazone skeletons.

pharmacological properties. One among the subsets of the hydrazone compounds occupies central roles in various drugs and natural products, for instance, nifuroxazide (A) functions as an intestinal antiseptic; compounds (B), exhibit anti-tubercular activity, compounds (C) show anti-thyroid cancer properties, while compound (D) displays analgesic and antibacterial activities (Fig. 1).^{40–43}

Motivated by such remarks and in continuation of our previous studies,^{44–47} the present work looks at the potential use of aldehydes as radical precursor sources in the synthesis of hydrazone-containing heterocyclic derivatives *via* Minisci-type reactions. This work attempts to offer a convenient, metal-free, and light-independent synthetic process that not only adheres to the principles of green chemistry but also offers a viable process for accessing novel heteroaromatic hydrazones of remarkable pharmaceutical promise.


Results and discussion

For the synthesis of heterocycles **4a–f**, initially, 2,4-dichloro-6-methyl-5-nitropyrimidine (**1**, synthesized by known method)⁴⁸ was stirred at room temperature with morpholine in chloroform for 2 h to obtain precursor **2**.⁴⁹ In the subsequent investigation, we hypothesized that the **2**, when treated with hydrazine hydrate in a mixture of triethylamine (Et₃N) and dimethylformamide (DMF), would undergo direct hydrazination. However, analysis revealed the formation of compound **3** (Scheme 1).

Several intermediates were isolated at different time points and their structures confirmed through spectral analysis. In the proposed mechanism, hydrazine hydrate and DMF initially


react, and the resulting product acts as a nucleophile attacking the chlorine atom in compound **2** at position 4, forming structure **I**.^{50–52} Then the reaction leads to the formation of a pyrazole ring, as in compound **II**. The presence of hydrazine hydrate subsequently causes the CH=N double bond to be reduced.^{53–55} Through sigmatropic shift of H[1,5] under thermal conditions a more stable product forms by rearranging π bonds, ultimately leading to the final compound **3** (Scheme 2).

In order to assay the Minisci reaction, the optimization studies were carried out using compound **3** and 4-isopropylbenzaldehyde as model substrates (Table 1). We investigated different oxidants and solvents to find suitable reaction conditions. Experiments conducted in acetonitrile, whether using trifluoroacetic acid (TFA) or sulfuric acid (H₂SO₄) (entries 1 and 2), using ammonium persulfate as the oxidant and dichloroethane (DCE) as the solvent, resulted in negligible product formation (entry 3), while replacing TFA with H₂SO₄ under the same conditions (entry 4) completely inhibited the reaction. In contrast, the combination of DCE, TFA, and potassium persulfate produced the desired product (yield = 85%) (entry 5), indicating that these conditions were optimal. The superior performance of K₂S₂O₈ compared to (NH₄)₂S₂O₈ may be attributed to its higher stability under the reaction conditions, which likely enables a more efficient and controlled generation of sulfate radical species. Alternative oxidants, such as benzoyl peroxide (entry 6), and solvents, such as DMF (entry 7), failed to improve the reaction efficiency. Furthermore, reactions conducted in DCE without the addition of acid (entry 8) or in the absence of solvent (entry 9) did not yield the desired product. The reaction was also performed at room temperature (entry 10); however, no product was observed, likely due to



Scheme 1 The schematic preparation of compound **3**.





Scheme 2 Plausible mechanism for the synthesis of compound 3.

Table 1 The optimization of the reaction conditions

Entry	Solvent	Acid	Oxidant	Time (h)	Temperature (°C)	Yield (%)
1	CH ₃ CN	TFA	K ₂ S ₂ O ₈	24	Reflux	—
2	CH ₃ CN	H ₂ SO ₄	K ₂ S ₂ O ₈	24	Reflux	—
3	DCE	TFA	(NH ₄) ₂ S ₂ O ₈	20	Reflux	Trace
4	DCE	H ₂ SO ₄	(NH ₄) ₂ S ₂ O ₈	24	Reflux	—
5	DCE	TFA	K₂S₂O₈	16	Reflux	85
6	DCE	TFA	Benzoyl peroxide	24	Reflux	—
7	DMF	TFA	K ₂ S ₂ O ₈	24	100	—
8	DCE	—	K ₂ S ₂ O ₈	24	Reflux	—
9	—	TFA	K ₂ S ₂ O ₈	24	100	—
10	DCE	TFA	K ₂ S ₂ O ₈	24	25	—

insufficient thermal activation of K₂S₂O₈ required to generate sulfate radical species. Overall, these studies identify dichloroethane as the appropriate solvent, trifluoroacetic acid as the acid, and potassium persulfate as the optimal oxidant in reflux conditions.


In the final step, products **4a–f** were synthesized by reacting compound **3** with various aldehyde derivatives in K₂S₂O₈ as a radical source, TFA as an acid catalyst, and dichloroethane as solvent under reflux conditions (Scheme 3).

Based on the literature reports^{56,57} and our studies, a plausible mechanism is proposed in Fig. 2. The Minisci reaction involves radical C–H functionalization of electron-deficient heteroarenes, in which aldehydes act as precursors to alkyl radicals *via* a decarbonylation pathway. Protonation of compound **3** with trifluoroacetic acid (TFA) increases its electrophilicity and directs radical addition to the most electron-

deficient sites. Initially, potassium persulfate decomposes under the reaction conditions to generate sulfate radicals, which initiate the transformation of aldehydes into alkyl radicals through a sequence of radical steps. Mechanistically, the sulfate radical first abstracts the formyl hydrogen of the aldehyde, yielding a transient acyl radical intermediate. This intermediate rapidly undergoes decarbonylation, extruding CO to furnish the corresponding alkyl radical. The alkyl radical then adds to the protonated heteroarene to form a radical cation, which ultimately provides the products **4a–f**.

All the structures were characterized, and the spectral data of one of the synthesized derivatives, 4-(2-(2-(4-isopropylbenzylidene)hydrazinyl)-6-methyl-5-nitropyrimidin-4-yl)morpholine **4a**, were reported. In the IR spectrum of this derivative, the stretching vibration bands appear at ν_{\max} 3277 cm⁻¹ (NH), whereas the IR spectrum of compound **3**





Scheme 3 The schematic preparation of derivatives 4a–f.

reveals the absence of an NH moiety. The C–H stretching vibrations of both aromatic and aliphatic groups appear in the range of $\nu = 2868\text{--}3133\text{ cm}^{-1}$, and symmetric and asymmetric

stretching vibrations of the nitro group in the range of $\nu = 1573, 1327\text{ cm}^{-1}$. In the $^1\text{H NMR}$ spectrum, a doublet signal at $\delta 1.23\text{ ppm}$ corresponds to six hydrogens of the isopropyl moiety




Fig. 2 The plausible mechanism for the synthesis of compounds 4a–f.






Fig. 3 Two-dimensional NOESY spectrum of compound 4e.

($-\text{CH}(\text{CH}_3)_2$). There is a single signal at δ 2.44 ppm corresponding to three hydrogens of the methyl of the pyrimidine ring, and a peak as a multiplet integrating for one hydrogen is associated, corresponding to ($-\text{CH}(\text{CH}_3)_2$) and two peaks appear as triplets in δ 3.48 ppm and δ 3.69 ppm, each integrating for four hydrogens, confirm the presence of the morpholine ring. Two peaks as a doublet signal at δ 7.32 ppm and δ 7.61 ppm, each integrating for two hydrogens, corresponded to the phenyl protons, and a signal at δ 8.16 ppm, corresponding to one hydrogen, is associated with ($-\text{CH}=\text{N}$). Also, the spectrum shows a singlet D_2O -exchangeable signal at δ 11.53 ppm, indicating the NH moiety. In the ^{13}C NMR spectrum, two groups of peaks are observed: five peaks in the aliphatic region corresponding to CH_3 -pyrimidine, and carbons of isopropyl and morpholine moieties. Nine signals appear in the aromatic region, eight of which correspond to the carbons of the pyrimidine and phenyl rings. In contrast, one signal at δ 144.4 ppm corresponds to the carbon of $\text{CH}=\text{N}$, confirming the true structure of this compound. Furthermore, Nuclear Overhauser Effect Spectroscopy (NOESY) was conducted on compound 4e. The two-dimensional NOESY spectrum, resembling the ^1H NMR spectrum, confirmed the spatial relationship between the $\text{CH}=\text{N}$ and NH protons, as evidenced by the presence of cross-peaks. This indicates that these two hydrogen atoms are in close proximity within the molecular structure. Additionally, the spatial relationship between the $\text{CH}=\text{N}$ and the morpholine protons is confirmed by the presence of cross-peaks (Fig. 3).

Eventually, the mass spectrum of this sample shows the molecular ion peak at $m/z = 384$ and a peak at $m/z = 219$, which corresponds to the cleavage of the nitro and isopropylbenzene groups from the main structure, confirming the synthesis of the

desired compound 4a. Attempted crystallography for compound 4a confirmed the connectivity of the atoms, but significant twinning did not allow the collection of publishable data for the crystal structure of this compound.

Conclusion

In summary, a protocol for the preparation of new derivatives of pyrimidine containing hydrazone substituents 4a–f has been reported and obtained by the metal-free and light-independent Minisci reaction. The synthetic method used radical precursors in the form of aldehydes and an oxidative medium mediated by $\text{K}_2\text{S}_2\text{O}_8$ -TFA, providing an efficient method for the direct functionalization of the pyrimidine derivatives containing the hydrazone 4a–f via C–C cross-coupling. The derivatives obtained were carefully characterized by using spectroscopic and microanalytical methods to confirm the structural framework. Pyrimidine–hydrazone moieties are of great interest because they have a wide biological spectrum.

Experimental

Melting points were measured by an Electrothermal Type 9200 melting point apparatus. The ^1H NMR (300 MHz) and the ^{13}C NMR (75 MHz) spectra were obtained on a Bruker Avance DRX-300 Fourier transform spectrometer. An Avatar 370 FT-IR Thermo Nicolet spectrometer was employed to record the IR spectra, and a Varian Mat CH-7 instrument for collecting mass spectra with 70 eV. Microanalytical data were obtained on a Thermo Finnigan Flash EA 1112 microanalyzer.



2-Chloro-6-methyl-4-morpholino-5-nitropyrimidine (2)

Yellow needle crystals; yield = 90%; m. p. 115–116 °C; IR (KBr disc, cm^{-1}): ν 3427, 2986, 2925, 2864, 1580, 1495, 1423, 1344, 1290, 1228, 1141. ^1H NMR (300 MHz, CDCl_3): δ_{H} 2.50 (s, 3H, CH_3), 3.60 (t, $J = 4.8$ Hz, 4H, morpholine), 3.78–3.82 (m, 4H, morpholine). ^{13}C NMR (75 MHz, CDCl_3): δ_{C} 21.3, 46.6, 66.3, 131.0, 154.8, 158.8, 163.5. MS (m/z) = 258 (M^+), 198 [$\text{M}^+ - (\text{Me}, \text{NO}_2)$], 128 [$\text{M}^+ - (\text{morpholine}, \text{NO}_2)$]. Anal. calcd for $\text{C}_9\text{H}_{11}\text{ClN}_4\text{O}_3$ (%): C, 41.79; H, 4.29; N, 21.66. Found: C, 41.77; H, 4.27; N, 21.64.

General procedure for the synthesis of compound (3)

To prepare 6-methyl-2-(methyldiazenyl)-4-morpholino-5-nitropyrimidine **3**, a solution of compound **2** (1 mmol, 0.258 g) in DMF (1 mL) was added to a mixture of hydrazine hydrate (0.24 mL, 5 mmol), triethylamine (0.3 mL, 2 mmol), and DMF (2 mL), which had been preheated to 50 °C. The resulting mixture was then stirred at 50 °C for 10 h. The progress of the reaction was monitored by TLC using chloroform : methanol (20 : 1) as eluent. After the completion of the reaction, the solvent was removed under reduced pressure, and the resulting solid was washed with water (2 × 20 mL) and dried.

N,N-Dimethyl-*N'*-(4-methyl-6-morpholino-5-nitropyrimidin-2-yl)formohydrazoneamide (I)

Brown powder; yield = 54%; m. p. 130–131 °C; IR (KBr disc, cm^{-1}): ν 3338, 3260, 3203, 3039, 2960, 2900, 1634, 1567, 1511, 1470, 1442, 1330, 1263. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ_{H} 2.26 (s, 3H, CH_3 -pyrimidine), 2.32–2.38 (m, 6H, $\text{N}(\text{CH}_3)_2$), 3.62–3.65 (m, 8H, morpholine), 5.80 (s, 1H, CH), 8.20 (s, 1H, NH). ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$): δ_{C} 24.9, 37.2, 47.2, 66.2, 123.9, 143.3, 158.6, 158.7, 163.8. MS (m/z) = 309 (M^+), 177 [$\text{M}^+ - (\text{morpholine}, \text{NO}_2)$]. Anal. calcd for $\text{C}_{12}\text{H}_{19}\text{N}_7\text{O}_3$ (%): C, 46.59; H, 6.19; N, 31.70. Found: C, 46.57; H, 6.17; N, 31.68.

4-(5-Methyl-6-nitro-[1,2,4]triazolo[4,3-*a*]pyrimidin-7-yl)morpholine (II)

Yellow powder; yield = 44%; m. p. 123–124 °C; IR (KBr disc, cm^{-1}): ν 3208, 3139, 3090, 2988, 2898, 2864, 1585, 1524, 1480, 1420, 1379, 1358, 1307, 1280, 1187. MS (m/z) = 264 (M^+), 218 [$\text{M}^+ - \text{NO}_2$], 178 [$\text{M}^+ - (\text{morpholine})$]. Anal. calcd for $\text{C}_{10}\text{H}_{12}\text{N}_6\text{O}_3$ (%): C, 45.45; H, 4.58; N, 31.80. Found: C, 45.43; H, 4.56; N, 31.78.

6-Methyl-2-(methyldiazenyl)-4-morpholino-5-nitropyrimidine (3)

Yellow powder; yield = 65%; m. p. 102–103 °C; IR (KBr disc, cm^{-1}): ν 3035, 2970, 2925, 2858, 1558, 1486, 1445, 1402, 1370, 1323, 1267, 1232, 1141. ^1H NMR (300 MHz, CDCl_3): δ_{H} 2.51 (s, 3H, CH_3 -pyrimidine), 3.22 (s, 3H, CH_3), 3.47–3.50 (m, 4H, morpholine), 3.76–3.79 (m, 4H, morpholine). ^{13}C NMR (75 MHz, CDCl_3): δ_{C} 23.6, 37.2, 47.2, 66.8, 124.3, 157.1, 158.7, 164.1. MS (m/z) = 266 (M^+), 220 [$\text{M}^+ - \text{NO}_2$], 135 [$\text{M}^+ - (\text{morpholine}, \text{NO}_2)$]. Anal. calcd for $\text{C}_{10}\text{H}_{14}\text{N}_6\text{O}_3$ (%): C, 45.11; H, 5.30; N, 31.56. Found: C, 45.09; H, 5.28; N, 31.54.

General procedure for the synthesis of compound (4a–f)

A mixture of 6-methyl-2-(methyldiazenyl)-4-morpholino-5-nitropyrimidine **3** (1 mmol, 0.266 g), various aldehyde derivatives (3 mmol), $\text{K}_2\text{S}_2\text{O}_8$ (2.3 mmol, 0.621 g), and TFA (1 mmol, 0.07 mL) in DCE (3 mL) was heated under reflux for 16 h. After completion of the reaction, which was monitored by TLC using CHCl_3 : MeOH (30 : 1), the solvent was evaporated under reduced pressure. Water (5 mL) was added, and the mixture was neutralized with an aqueous 5% NaHCO_3 solution. The mixture was extracted with EtOAc (3 × 10 mL), and the organic phase was dried over anhydrous Na_2SO_4 and evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel using CHCl_3 : MeOH (30 : 1) as eluent to yield the pure product.

4-(2-(2-(4-Isopropylbenzylidene)hydrazineyl)-6-methyl-5-nitropyrimidin-4-yl)morpholine (4a). Yellow powder; yield = 85%; m. p. 168–169 °C; IR (KBr disc, cm^{-1}): ν 3277, 3133, 2958, 2925, 2868, 1617, 1573, 1508, 1429, 1377, 1327, 1255. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ_{H} 1.23 (d, $J = 6.9$ Hz, 6H, 2 CH_3), 2.44 (s, 3H, CH_3 -pyrimidine), 2.92 (m, 1H, CH), 3.48 (t, $J = 4.8$ Hz, 4H, morpholine), 3.69 (t, $J = 4.7$ Hz, 4H, morpholine), 7.32 (d, $J = 8.1$ Hz, 2Ar-H), 7.61 (d, $J = 8.2$ Hz, 2Ar-H), 8.16 (s, 1H, CH), 11.53 (s, 1H, NH, D_2O exchangeable). ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$): δ_{C} 23.2, 24.2, 33.8, 47.0, 66.2, 125.2, 127.2, 127.3, 132.9, 137.3, 144.4, 150.5, 157.1, 164.1. MS (m/z) = 384 (M^+), 219 [$\text{M}^+ - (\text{isopropylbenzene}, \text{NO}_2)$]. Anal. calcd for $\text{C}_{19}\text{H}_{24}\text{N}_6\text{O}_3$ (%): C, 59.36; H, 6.29; N, 21.86. Found: C, 59.34; H, 6.27; N, 21.84.

Single crystals of compound **4a** were grown by slow evaporation of acetonitrile solution. For all observed crystals non-merohedral twinning with the presence of multiple domains was observed, and a non-twinned crystal could not be found. Application of other solvents did not allow single crystal growth. X-ray diffraction data collection (Mo $K\alpha$ radiation, 0.71073 Å wavelength) at 100 K temperature allowed to determine unit cell and space group ($a = 11.9529$ Å, $b = 13.3518$ Å, $c = 15.7124$ Å, $\alpha = 93.8315^\circ$, $\beta = 111.2006^\circ$, $\gamma = 113.9578^\circ$, space group $P\bar{1}$). The asymmetric unit contained two molecules of **4a** and one MeCN molecule. Although structure solution and refinement confirmed the atoms connectivity for compound **4a**, final R -factors ($R_1 = 0.2704$, $wR_2 = 0.4368$) made the structure not publishable. High R -factors are observed due to crystal twinning and inability to detwin the data using TWINABS software (in Bruker APEX II suite). To our surprise, the structure has not shown any disorder, and all hydrogen atoms were resolved in the difference Fourier map after location and anisotropic refinement of heavy atoms. Located H atoms as well confirmed the structure **4a**.

4-(2-(2-(4-Methoxybenzylidene)hydrazineyl)-6-methyl-5-nitropyrimidin-4-yl)morpholine (4b). Yellow powder; yield = 67%; m. p. 161–162 °C; IR (KBr disc, cm^{-1}): ν 3284, 2966, 2904, 2843, 1609, 1571, 1534, 1510, 1433, 1374, 1329, 1250, 1166. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ_{H} 2.43 (s, 3H, CH_3 -pyrimidine), 3.46–3.49 (m, 4H, morpholine), 3.67–3.70 (m, 4H, morpholine), 3.81 (m, 3H, O- CH_3), 6.99–7.02 (m, 2H, 2Ar-H), 7.62–7.65 (m, 2H, 2Ar-H), 8.14 (s, 1H, CH), 11.46 (s, 1H, NH). ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$): δ_{C} 23.3, 47.0, 55.7, 66.2, 108.8, 114.8, 125.4,



127.8, 128.7, 144.3, 157.1, 160.9, 164.2. MS (m/z) = 372 (M^+), 220 [M^+ - (methoxybenzene, NO_2)], 133 [M^+ - (methoxybenzene, morpholine, NO_2)]. Anal. calcd for $C_{17}H_{20}N_6O_4$ (%): C, 54.83; H, 5.41; N, 22.57. Found: C, 54.81; H, 5.39; N, 22.55.

4-((2-(4-Methyl-6-morpholino-5-nitropyrimidin-2-yl)hydrazineylidene)methyl)phenol (4c). Yellow powder; yield = 81%; m. p. 214–215 °C; IR (KBr disc, cm^{-1}): ν 3235, 2962, 2927, 2851, 1621, 1578, 1552, 1470, 1421, 1326, 1268, 1196. 1H NMR (300 MHz, $DMSO-d_6$): δ_H 2.53 (s, 3H, CH_3 -pyrimidine), 3.68–3.71 (m, 8H, morpholine), 6.89–6.95 (m, 3H, (2Ar-H, OH)), 7.28 (t, J = 7.8 Hz, 1H, Ar-H), 7.43 (d, J = 7.5 Hz, 1H, Ar-H), 8.35 (s, 1H, CH), 11.88 (s, 1H, NH). ^{13}C NMR (75 MHz, $DMSO-d_6$): δ_C 23.2, 47.1, 66.1, 116.9, 119.2, 119.7, 125.8, 130.3, 131.1, 145.7, 156.6, 156.8, 157.9, 164.3. MS (m/z) = 358 (M^+), 327 [M^+ - (OH, Me)], 220 [M^+ - (hydroxybenzol, NO_2)]. Anal. calcd for $C_{16}H_{18}N_6O_4$ (%): C, 53.63; H, 5.06; N, 23.45. Found: C, 53.61; H, 5.04; N, 23.43.

4-(2-(2-(4-Chlorobenzylidene)hydrazineyl)-6-methyl-5-nitropyrimidin-4-yl)morpholine (4d). Yellow powder; yield = 69%; m. p. 224–225 °C; IR (KBr disc, cm^{-1}): ν 3108, 2963, 2894, 2857, 1598, 1583, 1528, 1486, 1431, 1335, 1257, 1164. 1H NMR (300 MHz, $DMSO-d_6$): δ_H 2.44 (s, 3H, CH_3 -pyrimidine), 3.48–3.50 (m, 4H, morpholine), 3.68–3.71 (m, 4H, morpholine), 7.50 (d, J = 8.2 Hz, 2Ar-H), 7.71 (d, J = 8.2 Hz, 2Ar-H), 8.17 (s, 1H, CH), 11.63 (s, 1H, NH). ^{13}C NMR (75 MHz, $DMSO-d_6$): δ_C 23.1, 47.0, 66.2, 128.7, 129.3, 134.1, 134.3, 137.8, 141.1, 142.9, 156.7, 157.0, 164.1. MS (m/z) = 376 (M^+). Anal. calcd for $C_{16}H_{17}ClN_6O_3$ (%): C, 51.00; H, 4.55; N, 22.30. Found: C, 50.98; H, 4.53; N, 22.28.

4-(2-(2-(3-Bromobenzylidene)hydrazineyl)-6-methyl-5-nitropyrimidin-4-yl)morpholine (4e). Yellow powder; yield = 71%; m. p. 171–172 °C; IR (KBr disc, cm^{-1}): ν 3580, 3415, 3272, 3051, 2953, 2855, 1572, 1551, 1527, 1486, 1445, 1361, 1323, 1259. 1H NMR (300 MHz, $DMSO-d_6$): δ_H 2.53 (s, 3H, CH_3 -pyrimidine), 3.67–3.70 (m, 8H, morpholine), 7.36–7.42 (m, 1H, Ar-H), 7.57 (d, J = 7.9 Hz, 1H, Ar-H), 7.70 (d, J = 7.8 Hz, 1H, Ar-H), 7.85 (s, 1H, Ar-H), 8.15 (s, 1H, CH), 11.66 (s, 1H, NH). ^{13}C NMR (75 MHz, $DMSO-d_6$): δ_C 23.1, 47.0, 66.2, 122.6, 126.0, 129.4, 131.4, 132.3, 137.7, 142.4, 156.7, 157.0, 164.1. MS (m/z) = 421 (M^+), 220 [M^+ - (bromobenzene, NO_2)]. Anal. calcd for $C_{16}H_{17}BrN_6O_3$ (%): C, 45.62; H, 4.07; N, 19.95. Found: C, 45.60; H, 4.05; N, 19.93.

4-(6-Methyl-5-nitro-2-(2-(4-nitrobenzylidene)hydrazineyl)pyrimidin-4-yl)morpholine (4f). Yellow powder; yield = 65%; m. p. 240–241 °C; IR (KBr disc, cm^{-1}): ν 3313, 3195, 3064, 2962, 2923, 2865, 1579, 1550, 1508, 1446, 1339, 1253, 1169. 1H NMR (300 MHz, $DMSO-d_6$): δ_H 2.44 (s, 3H, CH_3 -pyrimidine), 3.49 (t, J = 4.7 Hz, 4H, morpholine), 3.68–3.71 (m, 4H, morpholine), 7.91–7.96 (m, 2H, Ar-H), 8.26–8.31 (m, 3H, (2Ar-H, CH)), 11.90 (s, 1H, NH). ^{13}C NMR (75 MHz, $DMSO-d_6$, ppm): δ_C 23.0, 47.0, 66.2, 124.6, 127.8, 128.9, 132.7, 141.5, 141.7, 147.7, 156.6, 157.1, 163.2, 164.1. MS (m/z) = 387 (M^+), 220 [M^+ - (nitrobenzene, NO_2)]. Anal. calcd for $C_{16}H_{17}N_7O_5$ (%): C, 49.61; H, 4.42; N, 25.31. Found: C, 49.59; H, 4.40; N, 25.29.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Data availability

The datasets used and analyzed in the current study are available in the supplementary information (SI). Supplementary information is available. See DOI: <https://doi.org/10.1039/d6ra01465h>.

Acknowledgements

The authors gratefully acknowledge the Research Council of Ferdowsi University of Mashhad (3/62964).

References

- 1 S. Jin, X. Geng, Y. Li and K. Zheng, *Eur. J. Org. Chem.*, 2021, **2021**, 969–972.
- 2 D. Xie, Y. Liu, X. Liu, Q. Yang and Y. Peng, *Eur. J. Org. Chem.*, 2024, **27**, e202300993.
- 3 K. A. Rinderspacher, *Prog. Heterocycl. Chem.*, 2015, **27**, 393–450.
- 4 R. S. J. Proctor and R. J. Phipps, *Angew. Chem., Int. Ed.*, 2019, **58**, 13666–13699.
- 5 F. Minisci, R. Bernardi, F. Bertini, R. Galli and M. Perchinnmo, *Tetrahedron*, 1971, **27**, 3575–3579.
- 6 O. Patel, N. Nandwana, L. J. Legoabe and A. Kumar, *Adv. Synth. Catal.*, 2020, **362**, 4226–4255.
- 7 J. Li, S. Siang Tan, S. H. Kyne and P. Wai Hong Chan, *Adv. Synth. Catal.*, 2022, **364**, 802–810.
- 8 M. Kemmochi, Y. Miyamoto, Y. Sumida and H. Ohmiya, *Asian J. Org. Chem.*, 2022, **11**, e202100640.
- 9 J. Jin and D. W. C. MacMillan, *Angew. Chem.*, 2015, **127**, 1585–1589.
- 10 F. J. A. Troyano, K. Anwar, F. Mohr, G. Robert and A. Gómez-Suárez, *Eur. J. Org. Chem.*, 2023, **26**, e202201176.
- 11 P. Chandra Tiwari, A. Pulcinella, E. Hodzic and T. Noel, *ACS Cent. Sci.*, 2025, **11**, 910–917.
- 12 M. A. J. Duncton, *Med. Chem. Commun.*, 2011, **2**, 1135–1161.
- 13 X.-Z. Wang and C.-C. Zeng, *Tetrahedron*, 2019, **75**, 1425–1430.
- 14 A.-L. Lee, D. T. Mooney and H. McKee, *Org. Biomol. Chem.*, 2024, **22**, 9145–9164.
- 15 E. Le Saux, E. Georgiou, I. A. Dmitriev, W. C. Hartley and P. Melchiorre, *J. Am. Chem. Soc.*, 2023, **145**, 47–52.
- 16 M. A. Graham, G. Noonan, J. H. Cheryman, J. J. Douglas, M. Gonzalez, L. V. Jackson, K. Leslie, Z. Liu, D. McKinney, R. H. Munday, C. D. Parsons, D. T. E. Whittaker, E. Zhang and J. Zhang, *Org. Process Res. Dev.*, 2021, **25**, 57–67.
- 17 J. Dong, F. Yue, J. Liu, H. Song, Y. Liu and Q. Wang, *Green Chem.*, 2021, **23**, 7963–7968.
- 18 E. R. Lopat'eva, I. B. Krylov, O. O. Segida, V. M. Merkulova, A. I. Ilovaisky and A. O. Terent'ev, *Molecules*, 2023, **28**, 934.
- 19 R. S. J. Proctor, H. J. Davis and R. J. Phipps, *Science*, 2018, **360**, 419–422.
- 20 A. M. Truscillo and C. Gambarotti, *Org. Process Res. Dev.*, 2019, **23**, 1450–1457.
- 21 W. Ali, A. Behera, S. Guin and B. K. Patel, *J. Org. Chem.*, 2015, **80**, 5625–5632.



- 22 M. T. Westwood, C. J. C. Lamb, D. R. Sutherland and A.-L. Lee, *Org. Lett.*, 2019, **21**, 7119–7123.
- 23 S. Mandal, T. Bera, G. Dubey, J. Saha and J. K. Laha, *ACS Catal.*, 2018, **8**, 5085–5144.
- 24 F. Doraghi, S. Kermaninia, E. S. Ghalehsefid, B. Larijani and M. Mahdavi, *RSC Adv.*, 2025, **15**, 14691–14716.
- 25 F. S. Meger and J. A. Murphy, *Molecules*, 2023, **28**, 6127.
- 26 K. Matcha and A. P. Antonchick, *Angew. Chem.*, 2013, **125**, 2136–2140.
- 27 Y. Siddaraju, M. Lamani and K. R. Prabhu, *J. Org. Chem.*, 2014, **79**, 3856–3865.
- 28 M. Qi and A.-W. Xu, *Org. Biomol. Chem.*, 2024, **22**, 2654–2661.
- 29 Z. Wang, X. Ji, J. Zhao and H. Huang, *Green Chem.*, 2019, **21**, 5512–5516.
- 30 O. Basl, J. Bidange, Q. Shuai and C.-J. Li, *Adv. Synth. Catal.*, 2010, **352**, 1145–1149.
- 31 A. Mahapatra, T. Prasad and T. Sharma, *Future J. Pharm. Sci.*, 2021, **7**, 123.
- 32 S. Eg and B. Lakshmanan, *Asian J. Pharm. Clin. Res.*, 2020, **13**, 30–34.
- 33 F. N. Gallo, A. B. Marquez, D. M. Fidalgo, A. Dana, M. Dellarole, C. C. Garcia and M. Bollini, *Eur. J. Med. Chem.*, 2024, **272**, 116465.
- 34 Y.-M. Tan, D. Li, F.-F. Li, M. Fawad Ansari, B. Fang and C.-H. Zhou, *Bioorg. Med. Chem. Lett.*, 2022, **73**, 128885.
- 35 M. S. Raghu, C. B. Pradeep Kumar, K. Yogesh Kumar, M. K. Prashanth, F. Alharethy and B.-H. Jeon, *Bioorg. Med. Chem. Lett.*, 2024, **103**, 129707.
- 36 H. Kuday, F. Sonmez, C. Bilen, E. Yavuz, N. Gençer and M. Kucukislamoglu, *BioMed Res. Int.*, 2014, **2014**, 594879.
- 37 M. Afzal, R. Mehmood, E. U. Mughal, N. Naeem, Z. Ashraf, Y. Nazir, F. M. Shalaby, A. El-Sayed Abd El Hady and A. Sadiq, *RSC Adv.*, 2024, **14**, 22769–22780.
- 38 S. Rollas and S. G. Küçükgülzel, *Molecules*, 2007, **12**, 1910–1939.
- 39 D. A. Tafere, M. Gebrezgiabher and F. Elemo, *RSC Adv.*, 2025, **15**, 6191–6207.
- 40 S. N. Mali, B. R. Thorat, D. R. Gupta and A. Pandey, *Eng. Proc.*, 2021, **11**, 21.
- 41 L. Yurttaş, Z. A. Kaplancıklı, Z. Cantürk and K. Gencer, *Phosphorus, Sulfur Silicon Relat. Elem.*, 2015, **190**, 1183–1191.
- 42 H. Li, M.-Q. Jia, Z.-L. Qin, C. Lu, W. Chu, Z. Zhang, J. Niu, J. Song, S.-Y. Zhang and L. Fu, *J. Enzyme Inhib. Med. Chem.*, 2024, **39**, 2423875.
- 43 B. Padmashali, B. N. Chidananda, B. Govindappa, S. M. Basavaraj, S. Chandrashekhara and K. N. Venugopala, *J. Appl. Pharm. Sci.*, 2019, **9**, 117–124.
- 44 A. Mirfarah, S. Hatami and A. Shiri, *RSC Adv.*, 2025, **15**, 42121–42175.
- 45 E. Vatankhah, H. Eshghi and A. Shiri, *J. Heterocycl. Chem.*, 2025, **62**, 1111–1118.
- 46 A. Tirehdast, S. Sheikhi-Mohammareh, H. Sabet-Sarvestani, M. G. Organ, V. Semeniuchenko and A. Shiri, *RSC Adv.*, 2024, **14**, 29122–29133.
- 47 P. Moghimi, H. Sabet-Sarvestani, O. Kohandel and A. Shiri, *J. Org. Chem.*, 2022, **87**, 3922–3933.
- 48 K. J. Hodgetts, T. Yoon, J. Huang, M. Gulianello, A. Kiełtyka, R. Primus, R. Brodbeck, S. De Lombaert and D. Doller, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 2497–2500.
- 49 S. M. Banihashemi, H. Hassani and J. Lari, *Russ. J. Org. Chem.*, 2020, **56**, 322–326.
- 50 Z.-B. Wu, X. Zhou, Y.-Q. Ye, P.-Y. Wang and S. Yang, *Chin. Chem. Lett.*, 2017, **28**, 121–125.
- 51 A. Katrusiak, A. Katrusiak and S. Bałoniak, *Tetrahedron*, 1994, **50**, 12933–12940.
- 52 S. H. Kwak and Y.-D. Gong, *Tetrahedron*, 2013, **69**, 7107–7111.
- 53 N. Menges and M. Balci, *Synlett*, 2014, **25**, 671–676.
- 54 B. J. Marsh and D. R. Carbery, *J. Org. Chem.*, 2009, **74**, 3186–3188.
- 55 C. Smit, M. W. Fraaije and A. J. Minnaard, *J. Org. Chem.*, 2008, **73**, 9482–9485.
- 56 X. Wang, X. Shao, Z. Cao, X. Wu and C. Zhu, *Adv. Synth. Catal.*, 2022, **364**, 1200–1204.
- 57 R.-J. Tang, L. Kang and L. Yang, *Adv. Synth. Catal.*, 2015, **357**, 2055–2060.

